The role transition of radiotherapy for the treatment of liver cancer  in the COVID-19 era

Zheng Li; Zheng Li; Yue Hu; Ming Zeng; Qinyong Hu; Fei Ye; Ruifeng Liu; Ruifeng Liu; Hongyi Cai; Qiang Li; Qiang Li; Xiaohu Wang; Xiaohu Wang

doi:10.3389/fonc.2022.976143

Frontiers in Oncology (Sep 2022)

The role transition of radiotherapy for the treatment of liver cancer in the COVID-19 era

Zheng Li,
Zheng Li,
Yue Hu,
Ming Zeng,
Qinyong Hu,
Fei Ye,
Ruifeng Liu,
Ruifeng Liu,
Hongyi Cai,
Qiang Li,
Qiang Li,
Xiaohu Wang,
Xiaohu Wang

Affiliations

Zheng Li: Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
Zheng Li: Lanzhou Heavy Ion Hospital, Lanzhou, China
Yue Hu: Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Ming Zeng: Department of Radiation Oncology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, United States
Qinyong Hu: Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
Fei Ye: Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
Ruifeng Liu: Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
Ruifeng Liu: Lanzhou Heavy Ion Hospital, Lanzhou, China
Hongyi Cai: Department of Radiotherapy, Gansu Provincial Hospital, Lanzhou, China
Qiang Li: Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
Qiang Li: Lanzhou Heavy Ion Hospital, Lanzhou, China
Xiaohu Wang: Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
Xiaohu Wang: Lanzhou Heavy Ion Hospital, Lanzhou, China

DOI: https://doi.org/10.3389/fonc.2022.976143
Journal volume & issue: Vol. 12

Abstract

Read online

The uncontrollable COVID-19 crises in the SARS-CoV-2 high-prevalence areas have greatly disrupted the routine treatment of liver cancer and triggered a role transformation of radiotherapy for liver cancer. The weight of radiotherapy in the treatment algorithm for liver cancer has been enlarged by the COVID-19 pandemic, which is helpful for the optimal risk-benefit profile.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords